Clevidipine

DEA Class; Rx

Common Brand Names; Cleviprex

• Calcium Channel Blockers; 
• Calcium Channel Blockers, Dihydropyridine

Intravenous dihydropyridine calcium channel blocker
Used for hypertension when oral therapy is not feasible or desirable
Delivered in a lipid emulsion vehicle

Indicated for the treatment of hypertension when oral therapy is not feasible or desirable.

Hypersensitivity to drug, soy or egg products

Defective lipid metabolism

Acute pancreatitis if accompanied by hyperlipidemia

Severe aortic stenosis

• AFib (21%)
• Nausea (21%)
• Acute renal failure (9%)
• Headache (6%)
• Vomiting (3%)
• Cardiac arrest
• Myocardial infarction
• Increased blood triglycerides
• Ileus
• Nausea
• Hypersensitivity
• Hypotension
• Reflex tachycardia
• Decreased oxygen saturation (possible pulmonary shunting)

Use aseptic technique and discard unused product within 12hr of stopper puncture

May produce systemic hypotension and reflex tachycardia; if either occurs, decrease dose of drug; there is limited experience with short-duration therapy with beta-blockers as a treatment for drug-induced tachycardia; beta-blocker use for this purpose not recommended

Drug contains approximately 0.2 g of lipid per mL (2.0 kcal); lipid intake restrictions may be necessary for patients with significant disorders of lipid metabolism; for these patients, a reduction in quantity of concurrently administered lipids may be necessary to compensate for amount of lipid infused as part of drug formulation

Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure; monitor heart failure patients carefully

Drug is not a beta-blocker, does not reduce heart rate, and gives no protection against effects of abrupt beta-blocker withdrawal; beta-blockers should be withdrawn only after gradual reduction in dose

Patients who receive prolonged infusions and are not transitioned to other antihypertensive therapies should be monitored for possibility of rebound hypertension for at least 8 hr after infusion is stopped

There is no information to guide use of drug in treating hypertension associated with pheochromocytoma

Available data based on post-marketing reports with use in pregnant women are not sufficient to inform a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes; there are risks to mother and fetus associated with poorly controlled hypertension in pregnancy

There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production